Glazer Capital LLC Makes New $3.07 Million Investment in Alimera Sciences, Inc. (NASDAQ:ALIM)

Glazer Capital LLC bought a new stake in Alimera Sciences, Inc. (NASDAQ:ALIM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 551,533 shares of the biopharmaceutical company’s stock, valued at approximately $3,067,000. Glazer Capital LLC owned 1.05% of Alimera Sciences as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Fifth Lane Capital LP acquired a new stake in Alimera Sciences in the first quarter worth about $83,000. Rhumbline Advisers bought a new stake in shares of Alimera Sciences during the second quarter worth approximately $113,000. Hillsdale Investment Management Inc. acquired a new position in Alimera Sciences in the first quarter valued at approximately $169,000. Bank of New York Mellon Corp bought a new position in Alimera Sciences in the second quarter valued at approximately $344,000. Finally, Gabelli Funds LLC acquired a new stake in Alimera Sciences during the 2nd quarter worth $600,000. 99.83% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Price Performance

Shares of ALIM stock opened at $5.54 on Tuesday. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. Alimera Sciences, Inc. has a 12-month low of $2.61 and a 12-month high of $5.65. The firm has a fifty day moving average of $5.56 and a 200-day moving average of $4.45. The firm has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. On average, equities research analysts forecast that Alimera Sciences, Inc. will post -0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALIM. StockNews.com initiated coverage on Alimera Sciences in a research note on Sunday. They issued a “hold” rating on the stock. HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research note on Tuesday, June 25th. Alliance Global Partners restated a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).